Limits...
Successful treatment of liver aspergilloma by caspofungin acetate first-line therapy in a non-immunocompromised patient.

Bai QX, Huan Y, Wang JH, Yang LJ, Dong HJ - Int J Mol Sci (2012)

Bottom Line: However, Aspergillus infection can be observed in non-immunocompromised individuals in rare cases.Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage.Our long-term follow-up study also revealed a favorable prognosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, State Allogeneic Hematopoietic Stem Cell Transplantation Center, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China; E-Mails: wangjh_2@163.com (J.-H.W.); yanglj_xj@126.com (L.-J.Y.); dhongjuanyahoo@163.com (H.-J.D.).

ABSTRACT
Aspergillosis remains to be a life-threatening complication in immunocompromised patients. However, Aspergillus infection can be observed in non-immunocompromised individuals in rare cases. We report a case of liver aspergilloma in a chronic aplastic anemia patient under relatively intact immune status. Therapeutic strategy for this rare condition was extensively discussed and caspofungin acetate single agent first-line therapy was applied after careful consideration. Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage. Our long-term follow-up study also revealed a favorable prognosis. Based on this experience, we suggest caspofungin acetate as first-line therapy for treatment plans of liver aspergilloma.

Show MeSH

Related in: MedlinePlus

After receiving two courses of caspofungin acetate first-line therapy, follow-up horizontal abdominal MRI image showed evident remission.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3472730&req=5

f3-ijms-13-11063: After receiving two courses of caspofungin acetate first-line therapy, follow-up horizontal abdominal MRI image showed evident remission.

Mentions: The patient was prescribed caspofungin acetate (Cancidas®, Merck Sharp & Dohme Pty. Ltd., Australia) according to the minimal inhibitory concentrations (MICs) tests. An antifungal regimen was started with caspofungin acetate 70 mg on day 1 and 50 mg daily from day 2 to day 10. Serum liver enzymes were monitored to interrupt potential adverse effects. The patient received one course of caspofungin acetate first-line therapy every month and responded well in the clinical symptoms. Two months after the initial diagnosis, repeated MRI images showed a significant reduction in the sizes and number of the liver nodules (Figure 3). Our patient underwent caspofungin acetate therapy for six months and was discharged. During our last time follow-up in May 2012, she was stable without signs of progression or recurrence.


Successful treatment of liver aspergilloma by caspofungin acetate first-line therapy in a non-immunocompromised patient.

Bai QX, Huan Y, Wang JH, Yang LJ, Dong HJ - Int J Mol Sci (2012)

After receiving two courses of caspofungin acetate first-line therapy, follow-up horizontal abdominal MRI image showed evident remission.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3472730&req=5

f3-ijms-13-11063: After receiving two courses of caspofungin acetate first-line therapy, follow-up horizontal abdominal MRI image showed evident remission.
Mentions: The patient was prescribed caspofungin acetate (Cancidas®, Merck Sharp & Dohme Pty. Ltd., Australia) according to the minimal inhibitory concentrations (MICs) tests. An antifungal regimen was started with caspofungin acetate 70 mg on day 1 and 50 mg daily from day 2 to day 10. Serum liver enzymes were monitored to interrupt potential adverse effects. The patient received one course of caspofungin acetate first-line therapy every month and responded well in the clinical symptoms. Two months after the initial diagnosis, repeated MRI images showed a significant reduction in the sizes and number of the liver nodules (Figure 3). Our patient underwent caspofungin acetate therapy for six months and was discharged. During our last time follow-up in May 2012, she was stable without signs of progression or recurrence.

Bottom Line: However, Aspergillus infection can be observed in non-immunocompromised individuals in rare cases.Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage.Our long-term follow-up study also revealed a favorable prognosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, State Allogeneic Hematopoietic Stem Cell Transplantation Center, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China; E-Mails: wangjh_2@163.com (J.-H.W.); yanglj_xj@126.com (L.-J.Y.); dhongjuanyahoo@163.com (H.-J.D.).

ABSTRACT
Aspergillosis remains to be a life-threatening complication in immunocompromised patients. However, Aspergillus infection can be observed in non-immunocompromised individuals in rare cases. We report a case of liver aspergilloma in a chronic aplastic anemia patient under relatively intact immune status. Therapeutic strategy for this rare condition was extensively discussed and caspofungin acetate single agent first-line therapy was applied after careful consideration. Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage. Our long-term follow-up study also revealed a favorable prognosis. Based on this experience, we suggest caspofungin acetate as first-line therapy for treatment plans of liver aspergilloma.

Show MeSH
Related in: MedlinePlus